Arbutus to Participate in Jefferies Global Healthcare Conference
Rhea-AI Summary
Arbutus Biopharma (Nasdaq: ABUS) announced it will participate in the Jefferies Global Healthcare Conference in New York. The company's management team is scheduled to present and hold one-on-one meetings with investors on June 5, 2024, at 9:30 am ET. Arbutus is focused on developing a functional cure for chronic hepatitis B (cHBV). A live webcast will be available, with an archived replay accessible on the Arbutus website for a time.
Positive
- Arbutus Biopharma's participation in the Jefferies Global Healthcare Conference can increase visibility and attract potential investors.
- Scheduled one-on-one meetings with investors may foster strategic partnerships and investments.
- The company is focused on a significant unmet medical need—developing a cure for chronic hepatitis B (cHBV).
Negative
- The announcement lacks specific updates on clinical progress or financial performance, which may disappoint some investors seeking concrete advancements.
- No new data or breakthroughs were shared, potentially limiting immediate positive impact on stock performance.
WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will present at and host one-on-one meetings at the following upcoming investor conference being held in New York:
Jefferies Global Healthcare Conference: Formal Presentation on June 5, 2024 at 9:30 am ET
To access the live webcast of the presentation, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in three Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
FAQ
When will Arbutus Biopharma present at the Jefferies Global Healthcare Conference?
Where can I access the live webcast of Arbutus Biopharma's presentation?
Will there be a replay available for Arbutus Biopharma's presentation at the Jefferies Global Healthcare Conference?
What is Arbutus Biopharma's stock symbol?
What is Arbutus Biopharma focusing on?
